Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 12,201,000 | 11,865,000 | 11,477,000 | 10,966,000 | 11,226,000 |
Cost of Goods | 3,267,000 | 2,932,000 | 2,745,000 | 2,506,000 | 2,876,000 |
Gross Profit | 8,934,000 | 8,933,000 | 8,732,000 | 8,460,000 | 8,350,000 |
Operating Expenses | 7,648,000 | 20,449,000 | 7,058,000 | 6,323,000 | 6,491,000 |
Operating Income | 1,286,000 | -11,516,000 | 1,674,000 | 2,137,000 | 1,859,000 |
Pre-tax Income | 1,286,000 | -11,516,000 | 1,674,000 | 2,137,000 | 1,859,000 |
Income Tax | -398,000 | 392,000 | -88,000 | 203,000 | -218,000 |
Net Income Continuous | 1,684,000 | -11,908,000 | 1,762,000 | 1,934,000 | 2,077,000 |
Minority Interests | 4,000 | 3,000 | N/A | 6,000 | 4,000 |
Net Income | $1,680,000 | $-11,911,000 | $1,762,000 | $1,928,000 | $2,073,000 |
EPS Basic Total Ops | 0.83 | -5.89 | 0.87 | 0.94 | 0.99 |
EPS Basic Continuous Ops | 0.83 | -5.89 | 0.87 | 0.94 | 0.99 |
EPS Diluted Total Ops | 0.83 | -5.89 | 0.87 | 0.93 | 0.99 |
EPS Diluted Continuous Ops | 0.83 | -5.89 | 0.87 | 0.94 | 0.99 |
EPS Diluted Before Non-Recurring Items | 2.07 | -4.40 | 1.70 | 2.00 | 1.75 |
EBITDA(a) | $3,882,000 | $-8,984,000 | $4,138,000 | $4,572,000 | $4,291,000 |